Revenues from Pfizer’s Vaccine Business Increase
According to a third-quarter earnings report, Pfizer’s vaccine business contributed nearly 14% to its total revenue.
Pfizer announced on Oct. 27, 2015 that compared with third-quarter earnings in 2014, revenues from its vaccine business increased by nearly 43%, and revenues specifically in the United States increased 78%, which the company said was driven by continued strong uptake of Prevnar 13 (pneumococcal 13-valent vaccine) among adults. Notably, global revenues in their oncology division increased by 54% operationally, which the company said was primarily driven by sales of their drug Ibrance (palbociclib) for the treatment of advanced breast cancer.
Although the company reported an increase in R&D expenses-primarily as a result of increased spending associated with its anti-PD-L1 alliance with Merck KGaA-the R&D spend increase was partially offset by lower clinical trial spending for certain vaccine programs.
The company also recently completed its acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY conjugate vaccines-Nimenrix and Mencevax-for approximately $130 million, but the company said it did not expect the acquisition to significantly affect its 2015 financial performance.
Source: Pfizer
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
